CMP Pharma Introduces Alcohol-Free Norliqva for Pediatrics

FARMVILLE, N.C., April 20, 2026

CMP Pharma, Inc. has announced the availability of a newly reformulated Norliqva® (amlodipine) oral solution, introducing an alcohol-free formulation designed to better meet the needs of pediatric and dysphagic patients. The updated formulation reflects a significant advancement in patient-centric pharmaceutical design, offering improved convenience, safety, and ease of administration for patients requiring hypertension treatment.

Improved Formulation Enhances Patient Convenience

The newly launched alcohol-free Norliqva oral solution (1 mg/mL) introduces multiple enhancements aimed at improving patient adherence and caregiver ease. Notably, the formulation eliminates the need for refrigeration and shaking, making it a ready-to-use, stable liquid medication suitable for a wide range of care settings.

The addition of a mixed berry flavor further enhances patient acceptability, particularly among children who may struggle with traditional tablet forms of medication. By addressing common challenges such as difficulty swallowing tablets (dysphagia) and inconsistencies associated with crushing or compounding medications, Norliqva offers a reliable, FDA-approved liquid alternative.

These improvements are particularly significant in pediatric care, where medication administration can often present challenges for both caregivers and healthcare providers. The ready-to-administer design simplifies dosing and reduces preparation errors, contributing to better treatment adherence and clinical outcomes.

Targeting Pediatric Hypertension with Safer Alternatives

Norliqva (amlodipine) is a calcium channel blocker indicated for the treatment of hypertension in adults and children aged six years and older, as well as certain forms of coronary artery disease. The introduction of an alcohol-free formulation is a critical step toward improving safety for younger patient populations, who may be more sensitive to excipients such as alcohol.

By removing alcohol from the formulation, CMP Pharma addresses an important clinical need, ensuring that the medication is better tolerated and more appropriate for long-term pediatric use. The reformulation aligns with broader trends in the pharmaceutical industry toward developing age-appropriate formulations that enhance safety and usability.

Healthcare professionals have emphasized the importance of having standardized liquid formulations, as opposed to compounded alternatives, which can vary in concentration and stability. Norliqva provides a consistent, regulated option that supports accurate dosing and reduces variability in treatment.

Strengthening Specialty Pharma Innovation

The launch of the new Norliqva formulation underscores CMP Pharma’s commitment to innovation in specialty pharmaceuticals, particularly in addressing niche patient populations with unmet medical needs. The company’s focus on oral liquid and semi-solid formulations enables it to deliver targeted solutions that improve patient experience and therapeutic outcomes.

By combining pharmaceutical expertise with patient-focused design, CMP Pharma continues to expand its portfolio of high-value medications that address gaps in existing treatment options. The availability of Norliqva through standard retail distribution channels ensures broad access for patients and healthcare providers.

This development also reflects a growing emphasis on personalized medicine and tailored drug delivery systems, where formulations are adapted to meet the specific needs of different patient groups, including children, elderly patients, and those with swallowing difficulties.

The introduction of the alcohol-free Norliqva oral solution marks a meaningful advancement in hypertension treatment, particularly for pediatric patients. With its enhanced convenience, improved safety profile, and patient-friendly features, the reformulated product exemplifies how innovative pharmaceutical design can improve adherence and clinical outcomes. CMP Pharma’s latest launch reinforces its role in delivering accessible, effective, and patient-centric therapies in the evolving healthcare landscape.

Source: CMP Pharma press release